Drug Trial Radar · NCT06347159
A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
79
Planned (sponsor's estimate)
Start
Apr 11, 2024
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Edgewise Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multiple doses in adults with obstructive or nonobstructive hypertrophic cardiomyopathy (nHCM).
Conditions
- Hypertrophic Cardiomyopathy
Interventions
EDG-7500Drug
Liquid suspension formulation of EDG-7500
EDG-7500Drug
Solid oral formulation of EDG-7500
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse eventsTime frame: From screening through study completion (Part A: Up to 38 days; Part B and C: Up to 73 days; Part D: Up to 18 months)
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
University of California, San Francisco
San Francisco, California
Stanford University Hospital / Stanford Health Care
Stanford, California
Emory Clinic
Atlanta, Georgia
Massachusetts General Hospital
Boston, Massachusetts
Brigham and Womens Hospital
Boston, Massachusetts
Lahey Hospital and Medical Center
Burlington, Massachusetts
Michigan Medicine - Michigan Clinical Research Unit
Ann Arbor, Michigan
Saint Luke's Hospital of Kansas City
Kansas City, Missouri
Morristown Medical Center (Atlantic Health System)
Morristown, New Jersey
North Shore University Hospital
Manhasset, New York
NYU Langone Health Medical Center - HCM Program Office (Study open to existing NYU patients only)
New York, New York
Sanger Heart and Vascular Institute
Charlotte, North Carolina
Duke Health Center Arringdon
Morrisville, North Carolina
The Lindner Research Center at Christ Hospital
Cincinnati, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Cleveland Clinic
Cleveland, Ohio
Oregon Health & Science University (OHSU)
Portland, Oregon
Hospital of the University of Pennsylvania (University of Pennsylvania School of Medicine)
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
University of Virginia Heart and Vascular Center Fontaine
Charlottesville, Virginia
Virginia Mason Medical Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.